Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTT-2: Baricitinib + Remdesivir for COVID-19
NCT04401579Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2020
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 8
01
Overview
A Phase 3 trial of baricitinib in coronavirus disease 2019 (COVID-19), sponsored by National Institute of Allergy and Infectious Diseases. Started May 2020; status: completed.
02
Drugs
baricitinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04401579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04401579.